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Evaluation of the impact of Dublin’s expanded
harm reduction programme on prevalence of
hepatitis C among short-term injecting drug users
Bobby P Smyth, Eamon Keenan, John J O’Connor
Injecting drug users represent a high risk group
for hepatitis C virus (HCV) infection and, in
many locations, the majority will test positive
for antibody to HCV (anti-HCV) within two
years of starting to inject.1 Although there is
evidence of a reduction in rates of unsafe
injecting,2 3 there is little published research
demonstrating that programmes that facilitate
safe injecting have reduced the occurrence of
HCV.4 Consequently, some commentators are
not optimistic that we will see a decrease in
HCV prevalence among injecting drug users.5
Harm reduction programmes include
methadone treatment, education regarding
safer injecting and the provision of syringe
exchange. These services vastly expanded in
Dublin over the period 1991 to late 1993. The
number of syringe exchange centres increased
from two to eight and the number of commu-
nity outreach workers and addiction counsel-
lors increased by 74%. We sought to test the
hypothesis that, among injecting drug users
with short injecting histories, the prevalence of
HCV would be lower in those who started
injecting during the period after this expansion
in services.
The setting for this study was Trinity Court,
which is the largest and longest established
addiction treatment centre in Dublin. Services
provided include counselling, methadone
maintenance and detoxification and assess-
ment regarding medical problems associated
with drug use such as HCV.
Patients, Method, and Results
Data have been recorded on an ongoing basis
on the results of all HCV tests on injecting drug
users attending Trinity Court since 1992. In
this study, consecutive new attenders, resident
in Dublin, with a reported injecting history less
than 25 months, tested for anti-HCV between
July 1993 and December 1996 were included.
We used a third generation enzyme linked
immunosorbent assay for anti-HCV ( Ortho
Clinical Diagnostics, Amersham, England).
Positive results were confirmed with a further
third generation test.
In all 353 injecting drug users were tested.
The primary drug of choice was heroin for
78%, morphine sulphate for 21%, and benzo-
diazepines for 1%.
Those with injecting histories of less than 13
months were over-represented in the group
that started injecting in the period after January
1994 (75.1% v 46.5%, ÷2 =30.4, p<0.001) and
they were more likely to misuse heroin (86.2%
v 68.6%, ÷2 = 15.7, p< 0.001). Period of com-
mencement of injecting was not significantly
associated with age, sex, employment or inject-
ing status of sexual partner (÷2 tests).
The prevalence of anti-HCV was 52.1%.
Univariate analysis showed that those who
started injecting in the period after January
1994 ( post-1993 group) and those with inject-
ing histories of less than 13 months demon-
strated significantly reduced risks of HCV
infection (see table 1). Age over 21 years was
weakly associated with increased risk.
Table 1 Period of commencement of injecting, duration injecting, age, sex, partner’s injecting status, principal drug injected, and employment status in
relation to risk for hapatitis C among injecting drug users with injecting histories of less than 25 months; univariate and multivariate analyses
Number
Prevalence of
anti-HCV (%)
Univariate analysis Multivariate analysis
Odds ratio (95%
confidence intervals) p value†
Odds ratio (95%
confidence intervals) p value
Period when commenced injecting
Before January 1994 (pre-’94 group) 172 64.5 1.0 1.0
After January 1994 (post-’93 group) 181 40.3 0.37 (0.24, 0.57) <0.001 0.43 (0.27, 0.67) <0.001
Duration since commenced injecting (months)
1 to 12 216 44.4 1.0 1.0
13 to 24 137 64.2 2.25 (1.45, 3.48) <0.001 1.76 (1.10, 2.80) 0.017
Age (years)
Under 21 168 47.0 1.0 1.0
21 and over 185 57.7 1.54 (1.01, 2.34) 0.044 1.51 (0.98, 2.34) 0.064
Sex
Male 241 51.0 1.0
Female 112 54.5 1.15 (0.73, 1.80) 0.55
Sexual partner’s injecting status*
Partner injecting 109 53.2 1.0
No partner injecting 236 52.1 0.96 (0.61, 1.51) 0.85
Primary drug injected
Heroin 274 52.2 1.0
Other 79 51.9 0.99 (0.60, 1.63) 0.96
Employment status
Employed 43 41.9 1.0
Unemployed 318 53.5 1.60 (0.84, 3.06) 0.15
* n=345, status of partner unknown for eight patients. † Pearson ÷2 test.
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Univariate analysis was repeated with data
stratified by length of injecting history (data
not shown). This demonstrated a significant
reduction in HCV in the post-1993 group with
injecting histories of less than 13months ( odds
ratio 0.36, (95% confidence intervals 0.21,
0.64) p=0.001) but the reduction was not sig-
nificant in those with injecting histories of 13
months and over (odds ratio 0.57, (95% confi-
dence intervals 0.28, 1.20) p=0.20).Multivari-
ate analysis was then performed with the three
variables that were significant on univariate
analysis being entered into a logistic regression
equation. This resulted in a weakening of the
association with duration since starting inject-
ing (see table 1). Also the eVect of age became
of borderline significance. There was no
evidence of interaction between independent
variables.
To further explore for the presence of a trend
of reducing prevalence of HCV, subjects were
ranked chronologically in terms of their date of
commencement of injecting and then divided
into thirds—that is, those who began injecting
before August 1993, those who started be-
tween August 1993 and July 1994 inclusive,
and thirdly, those who first injected after July
1994. Table 2 shows the highly significant
downward trend in HCV prevalence. When
data are stratified by length of injecting history,
the trend remains one of reducing HCV preva-
lence over time in both those with short and
longer injecting careers. However, the fall in
prevalence is statistically significant only in
those with injecting histories of less than 13
months.
Comment
The greater than twofold reduction in likeli-
hood of HCV infection provides some objec-
tive evidence of a decrease in unsafe injecting
practices after the service expansion. Unfortu-
nately, we were unable to control for other fac-
tors that may explain this decline in HCV.
Alternative explanations might include a possi-
ble reduction in overall injecting frequency
among the more recent injectors or continued
rates of unsafe injecting but confined within
safer groups. Therefore, while acknowledging
that our detection of a declining prevalence of
HCV infection after an expansion in harm
reduction services does not conclusively prove
causality, we believe that this is an encouraging
finding. However, we consider it premature to
assume that this protective eVect will persist
over time, as a reduced rate of unsafe injecting
by people within this group could still lead to a
very high prevalence of HCV infection.5 It may
simply take longer to do so.
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Table 2 Association between period of onset of injecting drug use and risk of hepatitis C, adjusted within strata of duration
of injecting drug use
Commenced injecting before
Aug ’93
Commenced injecting between
Aug ’93 and July ’94
Commenced injecting after
July ’94
p value*Number
Prevalence of
anti-HCV (%) Number
Prevalence of
anti-HCV (%) Number
Prevalence of
anti-HCV (%)
125 64.8 112 51.8 116 38.8 <0.001
Stratified by duration injecting (months)
1 to 12 48 60.4 73 46.6 95 34.7 0.003
13 to 24 77 67.5 39 61.5 21 57.1 0.33
* Mantel-Haenszel ÷2 test for trend.
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